ArticleTranslational lung cancer research2024
Construction and validation of deep learning model for cachexia in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors: a multicenter study.
Article in Translational lung cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of baseline LIPI, LDH and dNLR in ES-SCLC patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cachexia is observed in around 60% of patients with extensive-stage small cell lung cancer (ES-SCLC) and may play an important role in the development of resistance to immunotherapy. This study aims to evaluate the influence of cachexia on the effectiveness of immunotherapy, develop and assess a deep learning (DL)-based prediction model for cachexia, as well as its prognostic value. Methods: The analysis encompassed ES-SCLC patients who received the combination of first-line immunotherapy and chemotherapy from Shandong Cancer Hospital and Institute, Qilu Hospital, and Jining First People's Hospital. Survival analysis was conducted to examine the correlation between cachexia and the efficacy of immunotherapy. Medical records and computed tomography (CT) images of the third lumbar vertebra (L3) level were collected to construct the clinical model, radiomics, and DL models. The receiver operating characteristic (ROC) curve analysis was conducted to assess and analyze the efficacy of various models in detecting and evaluating the risk of cachexia. Results: A total of 231 ES-SCLC patients were enrolled in the study. Cachexia was related to inferior progression-free survival (PFS) and overall survival (OS). In internal and external validation cohorts, the area under the curve (AUC) of the DL model were 0.73 and 0.71. Conversely, the radiomics model in external validation cohort recorded an AUC of 0.67, highlighting the superior performance of the DL model and its demonstrated capability for effective generalization in external validation. All patients were categorized into two groups, namely high risk and low risk using the DL model. It was shown that patients with low-risk cachexia were associated with significantly prolonged PFS and OS. Conclusions: The DL model not only had better performance in predicting cachexia but also correlated with survival outcomes of ES-SCLC patients who receiving initial immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.